Loading...

APC/Cyanine7 anti-human CD16 Antibody

Pricing & Availability
Clone
3G8 (See other available formats)
Regulatory Status
RUO
Workshop
V NK80
Other Names
FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
3G8_APCCyanine7_CD16_Antibody_062019
Human peripheral blood lymphocytes stained with CD56 (NCAM) FITC and CD16 (clone 3G8) APC/Cyanine7 (left), or Mouse IgG1, κ APC/Cyanine7 isotype (right).
  • 3G8_APCCyanine7_CD16_Antibody_062019
    Human peripheral blood lymphocytes stained with CD56 (NCAM) FITC and CD16 (clone 3G8) APC/Cyanine7 (left), or Mouse IgG1, κ APC/Cyanine7 isotype (right).
See APC/Cyanine7 spectral data
Cat # Size Price Save
302017 25 tests ¥26,440
302018 100 tests ¥69,520
Description

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Product Details
Technical data sheet

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human PMN cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
  4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
  5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
  6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
  7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
  8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
  9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
  10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed
  11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
  16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  18. Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations
  1. McCracken M, et al. 2017. PLoS Pathog.. 10.1371/journal.ppat.1006487. PubMed
  2. Hydes T, et al. 2017. Immun Inflamm Dis. 10.1002/iid3.190. PubMed
  3. Felices M, et al. 2018. JCI Insight. 3. PubMed
  4. Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed
  5. Friedensohn S, et al. 2018. Front Immunol. 9:1401. PubMed
  6. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  7. Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed
  8. Hahn J, et al. 2019. Redox Biol. 26:101279. PubMed
  9. Ong SM, et al. 2019. Front Immunol. 10:1761. PubMed
  10. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  11. Dai HS et al. 2017. Immunity. 47(1):159-170 . PubMed
  12. Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed
  13. Dobbs KR, et al. 2017. JCI Insight. 2:e93684. PubMed
  14. Foote JR, et al. 2019. Front Immunol. 10:188. PubMed
  15. Flak MB, et al. 2020. J Clin Invest. 130:359. PubMed
  16. Wiedemann A, et al. 2020. Nat Commun. 3.048611111. PubMed
  17. Wiernik A, et al. 2013. Clin Cancer Res. 19:3844. PubMed
  18. Gleason M, et al. 2014. Blood. 123:3016. PubMed
  19. Weldon A, et al. 2015. J Rheumatol. 42:749. PubMed
  20. Bratcher P, et al. 2016. J Cystic Fibrosis. 15: 67-73. PubMed
  21. Romani B, et al. 2016. J Biol Chem. 291: 2696 - 2711. PubMed
  22. Vallera D, et al. 2016. Clin Cancer Res. 22: 3440 - 3450. PubMed
  23. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  24. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  25. Bäcker-Koduah P, et al. 2020. Ann Clin Transl Neurol. 1.422222222. PubMed
  26. Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed
  27. Sharma A, et al. 2020. Cell. 183(2):377-394.e21. PubMed
  28. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  29. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  30. Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed
  31. Mulder K, et al. 2021. Immunity. 54(8):1883-1900.e5. PubMed
  32. Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed
  33. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  34. Levy Y, et al. 2021. iScience. 24:102711. PubMed
  35. Jundi B, et al. 2021. JCI Insight. 6:e148866. PubMed
  36. Buters TP, et al. 2021. Br J Clin Pharmacol. Online ahead of print. PubMed
  37. Bekere I, et al. 2021. PLoS Pathog. 17:e1010074. PubMed
  38. Ponath V, et al. 2021. Int J Mol Sci. 22:. PubMed
  39. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  40. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  41. Port JR, et al. 2020. J Virol. 94:. PubMed
  42. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  43. Ireland RE, et al. 2022. Viruses. 14:. PubMed
  44. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  45. Lu H, et al. 2020. Am J Reprod Immunol. 83:. PubMed
  46. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  47. Hejazi M, et al. 2022. Front Immunol. 12:798087. PubMed
  48. Nie Y, et al. 2022. Virol J. 19:68. PubMed
  49. Ehlers L, et al. 2022. Int J Mol Sci. 23:. PubMed
  50. Masuta Y, et al. 2022. iScience. 25:105085. PubMed
  51. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  52. Fatehi Hassanabad A, et al. 2022. JTCVS Open. 12:118. PubMed
  53. Liisborg C, et al. 2022. Acta Ophthalmol. :3. PubMed
  54. Hastie KM, et al. 2023. Cell Rep. 42:112421. PubMed
RRID
AB_314217 (BioLegend Cat. No. 302017)
AB_314218 (BioLegend Cat. No. 302018)

Antigen Details

Structure
Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution

NK cells, activated monocytes, macrophages, neutrophils

Function
Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor
Aggregated IgG, IgG-antigen complex
Cell Type
Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Antigen References

1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
2. Stroncek D, et al. 1991. Blood 77:1572.
3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.

Gene ID
2214 View all products for this Gene ID
UniProt
View information about CD16 on UniProt.org

Related FAQs

Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?

Yes

Go To Top Version: 4    Revision Date: 06/20/2019

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account